Horizon Pharma (HZNP): Cutting PT Ahead of Earnings - Mizuho
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Horizon Pharma (NASDAQ: HZNP) and cut her price target to $29 from $33 ahead of earnings.
The lower price target accounts for a more price sensitive environment and increased rebates. The analyst still views HZNP as fundamentally undervalued even with conservative assumptions, but advises caution in front of the FA data read-out in late December. No change to the Buy rating.
Shares of Horizon Pharma closed at $17.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Preferred Bank (PFBC) PT Raised to $65 at FBR Capital Following 4Q EPS Beat
- Credit Suisse Starts Incyte (INCY) at Outperform, Says Jakafi Growth & Pipeline Expansion + Scarity Drives Bullish View
- Clovis Oncology (CLVS) PT Raised to $86 as Stifel Adopts Takeout Valuation
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesEarnings, Irina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!